RVTY250117C110000
- 9.00
- 0.000.00%
Revvity Newsroom
BofA Securities Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $138
TD Cowen Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $144
Stifel Maintains Revvity(RVTY.US) With Hold Rating, Maintains Target Price $120
TD Cowen Reaffirms Their Buy Rating on Revvity (RVTY)
BofA Securities Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $138
Revvity Receives Buy Rating for Strong Q4 Performance and Attractive Valuation
Bernstein Downgrades Revvity(RVTY.US) to Hold Rating, Cuts Target Price to $130
Bernstein Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $145
Bernstein Remains a Buy on Revvity (RVTY)
Evercore Maintains Revvity(RVTY.US) With Buy Rating, Cuts Target Price to $125
Citi Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $145
Revvity's Strategic Market Position and Anticipated Growth Drive Buy Rating
Revvity Analyst Ratings
BofA Securities Upgrades Revvity(RVTY.US) to Buy Rating, Announces Target Price $138
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Revvity (RVTY) and McKesson (MCK)
Stifel Nicolaus Remains a Hold on Revvity (RVTY)
Revvity Is Maintained at Overweight by Barclays
Revvity Analyst Ratings
Barclays Maintains Revvity(RVTY.US) With Buy Rating, Cuts Target Price to $135
Barclays Adjusts Price Target on Revvity to $135 From $140, Keeps Overweight Rating